Kips Biopharma (hereafter "Kips Pharma") announced on October 27 that its subsidiary, Kips Biomed, which is developing an oral drug delivery platform, will participate in "BIO-Europe 2025," to be held in Vienna, Austria, from November 3 to 5 (local time), with the aim of expanding global partnerships.
Now in its 31st year, BIO-Europe is the largest healthcare technology partnering event in Europe, attracting over 3,000 companies and organizations from around the world each year. During the event, more than 30,000 business meetings take place on average, focusing on partnerships between companies such as joint research, technology exports, and investment attraction.
Kips Biomed, having secured development momentum for its oral insulin formulation using the Oraloid™ technology through previous large-animal studies (beagle dogs and primates), plans to hold in-depth face-to-face meetings with numerous global pharmaceutical and biotech companies based on key preclinical trial data.
The company explained that, in particular, it will not only discuss joint development or partnership opportunities for its oral platform technology, which is attracting significant market attention, but will also explore technology in-licensing opportunities to further enhance the platform’s competitiveness, such as improving drug efficacy duration. Through global collaboration, Kips Biomed aims to further refine the global commercialization roadmap for its peptide-based drug delivery platform utilizing Oraloid technology.
Kips Biomed previously confirmed a relative bioavailability of 38% in preclinical studies of the oral insulin using Oraloid technology in beagle dogs, and also achieved a clinically meaningful absorption rate in primates sufficient for clinical entry.
A Kips Biomed representative stated, "We have already confirmed a sufficiently high absorption rate for oral GLP-1 to proceed to the next stage," adding, "We are currently optimizing the formulation, including changes to further improve absorption, with a view toward efficacy and toxicity evaluation as well as clinical entry." The representative continued, "We are coordinating meeting schedules with several biotech companies, including global pharmaceutical companies that have previously shown interest in or already held meetings regarding the Oraloid platform," and added, "We expect meaningful discussions that will contribute to expanding the platform and advancing commercialization."
Kips Biomed plans to enter the clinical phase for its oral insulin formulation using Oraloid technology in the first quarter of next year, while also accelerating the development of its oral GLP-1 formulation through increased investment, including the recruitment of additional research personnel.
Kim Hayong, CEO of Kips Pharma, said, "Participating in 'BIO-Europe 2025' is an important springboard for both validating the achievements of our Oraloid platform technology and increasing its commercial potential," adding, "As the platform validation and optimization stages for both oral insulin and oral GLP-1 are progressing smoothly, we will do our utmost to prove the value of our technology."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
